A recent study has found that the anti-nausea medication Aprepitant may do more than just prevent vomiting during chemotherapy.
It could also improve survival rates in women with early-stage breast cancer.
The strongest benefits were seen in those with triple negative breast cancer, a more aggressive form of the disease.
Image: Image from Shutterstock
Produced By: Moemina Shukur
Featured In Story: Dr Aeson Change – Senior Researched from Monash University
First aired on The Wire, Tuesday 15 July 2025